Vivus seeking broader Qsymia distribution

Vivus Inc. (NASDAQ:VVUS) submitted to FDA an amendment to the existing REMS for Qsymia phentermine/topiramate that would allow select retail pharmacies to distribute the obesity drug. The agency approved Qsymia in July with a REMS that requires the drug be distributed only through certified mail-order pharmacies. Vivus was off $0.41 to $22.30 on Tuesday. ...